Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZKAB001 maintenance after adjuvant chemotherapy for high-grade osteosarcoma
ChiCTR2000028785Phase 3Not yet recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of socazolimab in osteosarcoma (OS) (2 arms), sponsored by Shanghai Sixth People's Hospital. Primary endpoint: Disease-free survival. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
socazolimab
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on ChiCTR2000028785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000028785.